The gap between trailing and forward P/E suggests the market is discounting a sharp step-up in earnings power rather than paying for current profitability. Against its own recent history, the 13.57x forward EV/EBITDA multiple looks elevated for a company with a legacy immunology franchise facing IRA-driven pricing pressure. Relative to peers such as BMY at 9.35x EV/EBITDA, the premium appears to reflect obesity pipeline expectations rather than the core biologics base, which warrants monitoring of MariTide data.

The improvement in coverage suggests debt service has become considerably more comfortable as operating margins expanded to 35.8%. However, a debt-to-equity ratio still well above the sector norm indicates the balance sheet remains structurally leveraged following the Horizon acquisition. Investors should monitor whether further paydown continues, since the current position leaves limited cushion if pricing concessions reduce operating cash flow.

The stable and modest ROIC suggests that invested capital, heavily weighted toward goodwill and acquired intangibles, is generating returns well below the headline ROE. The ROE volatility appears to reflect a shrinking and rebuilding equity base rather than a structural shift in profitability. Investors should watch whether ROIC can rise durably toward the 5% range as acquisition-related asset bases are absorbed.

The negative cycle in recent quarters suggests suppliers are funding a substantial portion of operations, though this may reflect payables timing rather than structural efficiency. Inventory days moving between 193 and 323 indicate that buy-and-bill stocking patterns drive much of the volatility. Investors should treat the most recent negative CCC with caution until it proves repeatable across multiple periods.